Nathanael Gray, PhD

Nancy Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology in the Field of Medical Oncology, Dana-Farber Cancer Institute
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Authors: Authors: Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, Hunter ZR, Gray N, Treon SP.
Blood
View full abstract on Pubmed
The ins and outs of selective kinase inhibitor development.
Authors: Authors: Müller S, Chaikuad A, Gray NS, Knapp S.
Nat Chem Biol
View full abstract on Pubmed
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Authors: Authors: Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Jänne PA.
Clin Cancer Res
View full abstract on Pubmed
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Authors: Authors: Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE.
Oncotarget
View full abstract on Pubmed
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.
Authors: Authors: Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, Gray NS, Mitchison TJ, Zhao JJ.
Elife
View full abstract on Pubmed
Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.
Authors: Authors: Mistry H, Hsieh G, Buhrlage SJ, Huang M, Park E, Cuny GD, Galinsky I, Stone RM, Gray NS, D'Andrea AD, Parmar K.
Mol Cancer Ther
View full abstract on Pubmed
Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.
Authors: Authors: Zhang T, Hatcher JM, Teng M, Gray NS, Kostic M.
Cell Chem Biol
View full abstract on Pubmed
Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries.
Authors: Authors: Moret N, Clark NA, Hafner M, Wang Y, Lounkine E, Medvedovic M, Wang J, Gray N, Jenkins J, Sorger PK.
Cell Chem Biol
View full abstract on Pubmed
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Authors: Authors: Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, Qi J, Shapiro GI, Liu JF, Matulonis UA, Lin CY, Konstantinopoulos PA, Gray NS.
Elife
View full abstract on Pubmed
Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo.
Authors: Authors: Weir MC, Shu ST, Patel RK, Hellwig S, Chen L, Tan L, Gray NS, Smithgall TE.
ACS Chem Biol
View full abstract on Pubmed